Cystic fibrosis future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
In cystic fibrosis therapies under investigation include [[Prophylaxis|prophylactic]] [[ursodiol]] therapy; CF corrector VX-661; inhaled dry powder [[mannitol]] and [[CFTR (gene)|CFTR gene]] therapy. | In cystic fibrosis therapies under investigation include [[Prophylaxis|prophylactic]] [[ursodiol]] therapy; CF corrector VX-661; [[Inhalant|inhaled]] dry powder [[mannitol]] and [[CFTR (gene)|CFTR gene]] therapy. | ||
== future or investigational therapies == | == future or investigational therapies == | ||
| Line 11: | Line 11: | ||
* [[Prophylaxis|Prophylactic]] [[ursodiol]] therapy | * [[Prophylaxis|Prophylactic]] [[ursodiol]] therapy | ||
* CF corrector VX-661 | * CF corrector VX-661 | ||
* Inhaled dry powder [[mannitol]] | * [[Inhalation|Inhaled]] dry powder [[mannitol]] | ||
* [[CFTR (gene)|CFTR gene]] therapy | * [[CFTR (gene)|CFTR gene]] therapy | ||
Revision as of 19:12, 9 March 2018
|
Cystic fibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cystic fibrosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cystic fibrosis future or investigational therapies |
|
Cystic fibrosis future or investigational therapies in the news |
|
Blogs on Cystic fibrosis future or investigational therapies |
|
Risk calculators and risk factors for Cystic fibrosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
In cystic fibrosis therapies under investigation include prophylactic ursodiol therapy; CF corrector VX-661; inhaled dry powder mannitol and CFTR gene therapy.
future or investigational therapies
In cystic fibrosis therapies under investigation include:[1]
- Prophylactic ursodiol therapy
- CF corrector VX-661
- Inhaled dry powder mannitol
- CFTR gene therapy